Showing 1–12 of 13 results

Arimidex 1 mg Alternative – Anastrol (Anastrozole) 1 mg Tablet | Beacon Pharmaceuticals

Anastrol 1 mg (Anastrozole) Tablet by Beacon Pharmaceuticals. Reference brand: Arimidex. aromatase inhibitor; used in hormone receptor-positive breast cancer in postmenopausal patients. Prescription medicine. Brand comparison does not establish interchangeability.

Femara 2.5 mg Alternative – Lexel (Letrozole) 2.5 mg Tablet | Beacon Pharmaceuticals

Lexel 2.5 mg (Letrozole) Tablet by Beacon Pharmaceuticals. Reference brand: Femara. aromatase inhibitor; used in selected hormone receptor-positive breast cancer. Prescription medicine. Brand comparison does not establish interchangeability.

Ibrance 125 mg Alternative – Palbocent (Palbociclib) 125 mg Capsule | Incepta Pharmaceuticals

Palbocent 125 mg (Palbociclib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Ibrance (Pfizer).

Pack: 21 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.

Ibrance 125 mg Alternative – Palboxen (Palbociclib) 125 mg Capsule | Everest Pharmaceuticals

Palboxen 125 mg (Palbociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Ibrance (Pfizer). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.

Active ingredient: Palbociclib
Strength: 125 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Ibrance 125 mg Alternative – Palker (Palbociclib) 125 mg Capsule | Beacon Pharmaceuticals

Palker 125 mg (Palbociclib) Capsule by Beacon Pharmaceuticals. Reference brand: Ibrance. CDK4/6 inhibitor; used in selected HR-positive, HER2-negative breast cancer. Prescription medicine. Brand comparison does not establish interchangeability.

Kisqali 200 mg Alternative – Ribolib (Ribociclib) 200 mg Tablet | Beacon Pharmaceuticals

Ribolib 200 mg (Ribociclib) Tablet by Beacon Pharmaceuticals. Reference brand: Kisqali. CDK4/6 inhibitor; used in selected HR-positive, HER2-negative breast cancer. Prescription medicine. Brand comparison does not establish interchangeability.

Kisqali 200 mg Alternative – Riboxen (Ribociclib) 200 mg Tablet | Everest Pharmaceuticals

Riboxen 200 mg (Ribociclib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Kisqali (Novartis). It belongs to the CDK4/6 inhibitor class and is used in selected HR-positive, HER2-negative breast cancer regimens.

Active ingredient: Ribociclib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Nolvadex 20 mg Alternative – Tamoxi (Tamoxifen) 20 mg Tablet | Beacon Pharmaceuticals

Tamoxi 20 mg (Tamoxifen) Tablet by Beacon Pharmaceuticals. Reference brand: Nolvadex. selective estrogen receptor modulator; used in selected hormone receptor-positive breast cancer. Prescription medicine. Brand comparison does not establish interchangeability.

Piqray 150 mg Alternative – Alpesib (Alpelisib) 150 mg Tablet | Everest Pharmaceuticals

Alpesib 150 mg (Alpelisib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Piqray (Novartis). It belongs to the PI3K-alpha inhibitor class and is used in selected PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer regimens.

Active ingredient: Alpelisib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Talzenna 1 mg Alternative – Talaparib (Talazoparib) 1 mg Capsule | Everest Pharmaceuticals

Talaparib 1 mg (Talazoparib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Talzenna (Pfizer). It belongs to the PARP inhibitor class and is used in selected genetically defined breast and prostate cancer treatment settings.

Active ingredient: Talazoparib
Strength: 1 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Tukysa 150 mg Alternative – Tucaxen (Tucatinib) 150 mg Tablet | Everest Pharmaceuticals

Tucaxen 150 mg (Tucatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tukysa (Seagen / Pfizer). It belongs to the HER2 tyrosine kinase inhibitor class and is used in selected HER2-positive breast cancer treatment combinations.

Active ingredient: Tucatinib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh

Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Tykerb / Tyverb 250 mg Alternative – Lapacent (Lapatinib) 250 mg Tablet | Incepta Pharmaceuticals

Lapacent 250 mg (Lapatinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Tykerb / Tyverb (Novartis).

Pack: 12 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.